Regulatory bodies employ a combination of risk assessment and management strategies. These include pre-market evaluations, post-market surveillance, and specific guidelines for exposure limits. For instance, the FDA has specific guidelines for nanomaterials in drug products, focusing on their pharmacokinetics, toxicity, and long-term effects.
